KM 11060 is a corrects F508del-CFTR trafficking; increases the amount of functional CFTR at the plasma membrane (~75%). Shown to inhibit PDE5 activity.
|Solubility (25°C)||DMSO 42.23 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Olezarsen, an N-acetylgalactosamine (GalNAc)-suffixed antisense oligonucleotide (ASO) targeting hepatic APOC3 mRNA, inhibits the production of apolipoprotein C-III (apoC-III) and can be used in studies related to familial celiac sprue syndrome (FCS).
Lumasiran is a siRNA compound that reduces hepatic oxalate production by targeting ethanoic acid oxidase.
Givosiran is a small interfering RNA that targets hepatic aminofibrillar synthase 1 (ALAS1) messenger RNA, down-regulates ALAS1 mRNA, and prevents the accumulation of neurotoxic Î±-aminofibrillar acids and porphyrins, which can be used in porphyria-related studies.
Viltolarsen is a phosphorodiamidomorpholine antisense oligonucleotide that targets splicing of exon 53 of the myotonic dystrophy protein gene and can be used in the study of Duchenne muscular dystrophy (DMD).
Golodirsen is a phosphodiesteric morpholino oligomer (PMO) that specifically targets exon 53 of the pre-protein mRNA of myotonic dystrophy protein culture proteins, and can be used in studies related to Duchenne muscular dystrophy (DMD).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.